Journey Medical Corporation Form 8-K Summary
Business Context and Reporting Period
Journey Medical Corporation filed a Form 8-K regarding a Nasdaq continued-listing deficiency. The deficiency was based on the company’s Form 10-Q for the quarter ended June 30, 2023. The Nasdaq notification was received on August 15, 2023; the filing was signed on August 18, 2023.
Key Financial Metrics and Liquidity
- Reported stockholders’ equity: $5,000 as of June 30, 2023.
- Nasdaq minimum stockholders’ equity requirement: $2.5 million.
- The filing does not provide clear values for revenue, net income, cash flow, margins, debt, cash, or other liquidity metrics.
Material Change Versus Prior Period
The material event is Nasdaq’s determination that the company does not comply with Listing Rule 5550(b)(1). The filing does not provide comparable prior-period financial data or explain the period-over-period change in stockholders’ equity.
Outlook, Risks, and Contingencies
- Journey has 45 calendar days from August 15, 2023 to submit a compliance plan and intends to do so.
- If Nasdaq accepts the plan, it may grant up to 180 additional calendar days to demonstrate compliance.
- If the plan is rejected, or the company fails to regain compliance during an extension, Journey may request a hearing before an independent panel. A hearing request would stay suspension or delisting actions pending the hearing process and any additional extension granted.
- The deficiency has no immediate effect on the listing or trading of the common stock, which continues to trade on Nasdaq under ticker DERM.
- There is no assurance that Nasdaq will grant an extension or that Journey will regain compliance. Potential delisting is a stated risk.
- Other disclosed risks include competition and generic products, regulatory and clinical-development risks, dependence on dermatology product sales and DFD-29, reliance on third parties, intellectual-property risks, cybersecurity threats, potential need for additional capital, and Fortress’s voting control.
Important Facts for Investors to Verify
- Whether Journey submitted its compliance plan within the 45-day deadline.
- Whether Nasdaq accepted the plan and granted an extension.
- The company’s subsequent stockholders’ equity, cash position, debt, operating results, and financing activity.
- Whether the company ultimately regained compliance or pursued a Nasdaq hearing.
- Any subsequent Nasdaq notices, suspension actions, delisting proceedings, or changes in trading status.